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Abstract
Purpose: To assess the impact of two multileaf collimator (MLC) systems (2.5 and 5 mm leaf widths) on
three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and dynamic conformal arc
techniques for stereotactic body radiation therapy (SBRT) of liver and lung lesions.
Methods: Twenty-nine SBRT plans of primary liver (n = 11) and lung (n = 18) tumors were the basis of
this study. Five-millimeter leaf width 120-leaf Varian Millennium (M120) MLC-based plans served as
reference, and were designed using static conformal beams (3DCRT), sliding-window intensity-modulated
beams (IMRT), or dynamic conformal arcs (DCA). Reference plans were either re-optimized or
recomputed, with identical planning parameters, for a 2.5-mm width 120-leaf BrainLAB/Varian high-
definition (HD120) MLC system. Dose computation was based on the anisotropic analytical algorithm
(AAA, Varian Medical Systems) with tissue heterogeneity taken into account. Each plan was normalized
such that 100% of the prescription dose covered 95% of the planning target volume (PTV). Isodose
distributions and dose-volume histograms (DVHs) were computed and plans were evaluated with respect
to target coverage criteria, normal tissue sparing criteria, as well as treatment efficiency.
Results: Dosimetric differences achieved using M120 and the HD120 MLC planning were generally small.
Dose conformality improved in 51.7%, 62.1% and 55.2% of the IMRT, 3DCRT and DCA cases, respectively,
with use of the HD120 MLC system. Dose heterogeneity increased in 75.9%, 51.7%, and 55.2% of the
IMRT, 3DCRT and DCA cases, respectively, with use of the HD120 MLC system. DVH curves
demonstrated a decreased volume of normal tissue irradiated to the lower (90%, 50% and 25%) isodose
levels with the HD120 MLC.
Conclusion: Data derived from the present comparative assessment suggest dosimetric merit of the high
definition MLC system over the millennium MLC system. However, the clinical significance of these results
warrants further investigation in order to determine whether the observed dosimetric advantages
translate into outcome improvements.
Published: 10 July 2009
Radiation Oncology 2009, 4:22 doi:10.1186/1748-717X-4-22
Received: 17 November 2008
Accepted: 10 July 2009
This article is available from: http://www.ro-journal.com/content/4/1/22
© 2009 Tanyi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Radiation Oncology 2009, 4:22 http://www.ro-journal.com/content/4/1/22
Page 2 of 7
(page number not for citation purposes)
Background
Stereotactic body radiation therapy (SBRT) is a modern
precision radiation therapy delivery concept characterized
by one to five fraction delivery of focal high-dose radia-
tion [1,2]. SBRT has become an established treatment
technique for lung [3-5], liver [6-8], and spinal lesions [9-
11]. Conceptually derived from cranial stereotactic radio-
surgery, the planning and delivery of SBRT is characterized
by highly target-conformal dose distributions with steep
dose gradients towards normal tissues, which allow the
administration of potent tumor-ablative radiation doses.
Beam shaping for linear accelerator-based SBRT planning
and delivery is mostly afforded by multileaf collimator
(MLC) systems. Over the last 15 years, MLCs have evolved
in terms of both field size and width of the individual
tungsten leafs, and it is intuitive to assume that target dose
conformity and/or the steepness of the dose gradient can
be influenced by decreasing MLC leaf width [12-23]. The
current work seeks to assess if a novel high-definition 2.5-
mm leaf MLC system (HD-MLC) integrated into a dedi-
cated stereotactic linear accelerator system (BrainLAB/Var-
ian Novalis TX) provides dosimetric advantages compared
with a clinically widely utilized 5 mm leaf system for SBRT
of lung and liver lesions, and if potential gains realized
may be clinically meaningful.
Materials and methods
Patients and treatment protocol
The present study is based on 29 patients that had under-
gone a course of SBRT at Oregon Health & Science Univer-
sity in Portland, Oregon, USA between July 2007 and May
2008. The patient population included 18 primary early
stage lung tumors and 11 hepatocellular carcinoma
(HCC). Clinical treatment planning simulation imaging
and SBRT delivery were performed with patients immobi-
lized in a double vacuum whole-body immobilization
system (BodyFix; Medical Intelligence, Schwabmuenchen,
Germany). The basis for SBRT was thin slice CT scans
acquired on a dedicated 16 slice big-bore CT simulator
(Philips Medical Systems, Cleveland, OH, USA). The
imaging data was electronically transferred to the Eclipse
radiation therapy planning system (Varian Medical Sys-
tems, Palo Alto, CA, USA). Based on both free-breathing
and respiration resolved 4DCT scans, the internal target
volume (ITV) was delineated and expanded into a plan-
ning target volume (PTV) by adding isotropic 5 mm mar-
gins. All clinical SBRT plans (reference plans) were
computed using a multiple static field sliding-window
IMRT technique for delivery on the Varian Trilogy plat-
form (Varian Medical Systems, Palo Alto, CA) equipped
with a 120-leaf Millennium MLC (M120 MLC) system,
with forty 5-mm central leaf-pairs and twenty 10-mm
peripheral leaf-pairs. The anisotropic analytical algorithm
(AAA) was used for dose computation with a dose calcu-
lation grid of 2.5 mm3. Tissue heterogeneity was taken
into account. All treatments were planned for five fraction
delivery (10 Gy/fraction for liver tumors, and 12 Gy/frac-
tion for lung lesions). All plans were computed such that
the prescribed dose (PD) encompassed 95% of the PTV,
with a heterogeneous dose distribution and a desired plan
maximum of 150% of PD.
Comparative plans were generated from corresponding
reference IMRT plans by re-optimization for the Novalis
TX treatment platform (Varian Medical Systems),
equipped with a high-definition MLC (HD120 MLC) sys-
tem with thirty-two 2.5-mm central leaf-pairs and twenty-
eight 5-mm peripheral leaf-pairs. To assure valid data gen-
eration, all reference plans were carefully selected from a
larger library of SBRT plans to ensure that PTVs were con-
formed by the central 5 mm leafs of the Varian Trilogy
platform, and correspondingly, only the central 2.5 mm
leafs of the Novalis TX platform for the comparative plans.
In addition to the influence of the respective MLC system
on IMRT-based SBRT dose distributions, the impact of
MLC system was also investigated for commonly utilized
static three-dimensional conformal radiation therapy
(3DCRT), and dynamic conformal arc (DCA) planning
techniques. Hence, besides the available M120 MLC IMRT
reference plan, the following five alternative treatment
plans were generated for each patient: (1) HD120 MLC
IMRT, (2) M120 MLC 3DCRT, (3) HD120 MLC 3DCRT,
(4) M120 MLC DCA, and (5) HD120 MLC DCA. Nine to
twelve beams were used to generate the IMRT and 3DCRT
plans. Beam angles were arranged in a practical manner
according to tumor and critical organ location for the pur-
pose of achieving maximal target coverage and optimal
dose distribution conformity while keeping doses to OAR
(including the contralateral lung, liver, spinal cord,
esophagus, bowel, and ipsilateral kidney) below institu-
tional dose limits.
Evaluation parameters
All study cases were categorized into five groups according
to ITVs: category O; all ITVs, category I; 1 ≤ ITV < 8 cm3,
category II; 8 ≤ ITV < 27 cm3, category III; 27 ≤ ITV < 64
cm3, and category IV; ITV ≥ 64 cm3. Categories I though IV
were selected because they each equaled the volumes of
cubes with side length of 1, 2, 3, and 4 cm, respectively
[19].
Each treatment plan was evaluated with respect to target
coverage criteria, normal tissue sparing criteria, as well as
treatment efficiency. In terms of target coverage criteria,
PTV dose-volume histogram (DVH) parameters including
mean dose (or Dmean, defined in this study as the sum of
the product of dose value and percent volume in each
dose bin), minimum dose (or Dmin, defined in this studyRadiation Oncology 2009, 4:22 http://www.ro-journal.com/content/4/1/22
Page 3 of 7
(page number not for citation purposes)
as dose to 99% of the PTV) and maximum dose (or Dmax,
defined in this study as dose received by the "hottest" 3%
volume of the PTV) were computed and recorded. The
conformity of each treatment plan was quantified using a
robust conformity index (CI) based on formulations by
Paddick [24] and Nakamura et al. [25]
where PIS is the prescription isodose surface, VPTV is the
magnitude of the planning target volume, VPIS is the vol-
ume encompassed by the prescription isodose surface,
and PTVPIS is the planning target volume encompassed
within the prescription isodose surface. Since all plans in
the current study were normalized such that 95% of the
planning target volume was conformally covered by the
prescription isodose surface, the PTVPIS is 95% of the VPTV.
Also, target dose heterogeneity was assessed using a heter-
ogeneity index (HI) define below:
By considering normal tissue outside the PTV but in the
dose volume space as a virtual structure, dose-spillage vol-
umes [26] were computed to assess normal tissue sparing
effect of the MLC systems. The following dose spillage vol-
umes were assessed: 1) VHS or high-dose spillage volume
taking into account normal tissue receiving an ablative
dose; that is, ≥ 90% of the prescription dose in the current
study, 2) VIS or intermediate-dose spillage volume taking
into account normal tissue receiving a significant fraction
of the prescription dose; that is, ≥ 50% of the prescription
dose, and 3) VLS or low-dose spillage volume taking into
CI
VPTV VPIS
PTVPIS
=
´
[]
2 , (1)
HI
Dmax Dmin
Dmean
=
-
. (2)
Isodose distributions and DVHs for a lung lesion generated from three different planning techniques and two MLC systems Figure 1
Isodose distributions and DVHs for a lung lesion generated from three different planning techniques and two 
MLC systems. A1 through A6 are axial isodose distribution corresponding to M120 MLC IMRT, M120 MLC 3DCRT, M120 
MLC DCA, HD120 MLC IMRT, HD120 MLC 3DCRT, and HD120 MLC DCA plans, respectively.Radiation Oncology 2009, 4:22 http://www.ro-journal.com/content/4/1/22
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account normal tissue receiving low doses of radiation;
that is, ≥ 25% of the prescription dose.
Finally, the efficiency of each treatment plan was com-
puted as a ratio of the cumulative sum of monitor units
(MUs) per fraction to the dose per fraction. A paired t-test
with two-tailed distribution, and a p-value < 0.05 defining
statistical significance, was used to assess whether differ-
ences between the MLC systems were statistically signifi-
cant.
Results
Target dose-volume parameters
The median ITV and PTV for all 29 cases in the current
study were 7.58 cm3 [range: 1.03–91.53 cm3] and 26.33
cm3 [range: 13.95–167.44 cm3], respectively. The DVHs
and corresponding isodose distributions for all involved
treatment planning techniques are shown for a represent-
ative lung cancer case in Figure 1. Additional file 1 sum-
marizes the median mean, minimal and maximal PTV
doses for each planning technique, separated in terms of
treatment site and MLC system. Overall, there was
demonstrable quantitative difference between corre-
sponding HD120 MLC and M120 MLC PTV doses,
although not every perceived difference was statistically
significant.
Target dose conformity and normal/critical structure dose
The mean values of the conformity and heterogeneity
indices, along with p-values of paired t-tests comparing
corresponding planning techniques of the MLC systems
under consideration, are summarized in Additional file 2
according to ITV groups. Overall, HD120 MLC plans
exhibited better conformity than M120 MLC plans.
Unlike the IMRT cases where no clear trend was exhibited
for the mean conformity and heterogeneity indices, plans
of both 3DCRT and DCA showed a decreasing pattern
with increasing ITV. Furthermore, the conformity index
either stayed the same or increased with increasing MLC
leaf width. However, unlike the conformity index, the het-
erogeneity index either stayed the same or decreased with
increasing MLC leaf width. Despite these perceived quan-
titative differences, all but two the p-values of paired t-tests
of the conformity index between the different MLC plans
were greater than 0.05.
Additional file 3 summarizes the median dose to OAR
(including the spinal cord, esophagus, ipsilateral kidney,
ipsilateral lung, and liver). For the spinal cord and the
esophagus, the magnitude of the range of values was
determined by the proximity of the OAR to the PTV. The
volume of normal tissue irradiated to ≥ 90%, ≥ 50% and
≥ 25% of the prescription dose, normalized to the plan-
ning target volume, is summarized in Table 1, along with
p-values of paired t-tests comparing corresponding plan-
ning techniques of the MLC systems under consideration.
The results indicate an overall lower dose spillage from
the HD120 MLC compared with the M120 MLC. The
number and percentage of patient plans with improved
performance of the HD120 MLC over the M120 MLC are
shown in Table 2, while Table 3 summarizes the mean
and maximum absolute percent improvement.
Planning efficiency
The mean value of the total number of MUs necessary to
deliver the prescribed dose per fraction for all patients and
respective treatment plan category are presented in
Table 4.
The mean MU/cGy for the HD120 MLC system was
slightly higher for IMRT plans. However, there was virtu-
ally no difference between the MLC systems for the
3DCRT and DCA cases.
Discussion
One of the most compelling studies to assess the impact
of MLCs on dose distributions was performed by Bortfeld
et al. [15]. The authors show that the theoretically calcu-
lated optimal leaf width for a 6 MV photon beam is in the
range of 1.5–2 mm. Of all the practical studies that have
been conducted, there is utter agreement that by changing
MLC widths from 10 mm to 5–3 mm the results are both
statistically and clinically significant [12,13,17-21]. Dosi-
metric improvements reported by such studies, if applied
to the SBRT process, may reduce chronic normal/critical
structure injuries as the percentage volume of these struc-
Table 1: Mean dose-spillage volume, normalized to PTV.p-values of the paired t-test included to assess difference between MLC 
systems.
Technique VHS VIS VLS
M120 HD120 M120 HD120 M120 HD120
IMRT 0.54 ± 0.30 0.50 ± 0.25 3.86 ± 1.38 3.66 ± 1.22 23.69 ± 9.21 23.14 ± 8.75
p = 0.07 p = 0.03 p = 0.08
3DCRT 0.47 ± 0.13 0.44 ± 0.10 4.08 ± 1.34 3.93 ± 1.12 23.64 ± 7.70 23.36 ± 7.70
p = 0.04 p = 0.24 p = 0.01
DCA 0.44 ± 0.13 0.43 ± 0.12 3.26 ± 0.61 3.19 ± 0.60 15.32 ± 4.36 14.76 ± 4.23
p = 0.34 p = 0.06 p = 0.03Radiation Oncology 2009, 4:22 http://www.ro-journal.com/content/4/1/22
Page 5 of 7
(page number not for citation purposes)
tures receiving all ranges of dose is in effect reduced. Fur-
thermore, for the PTV, increased maximum dose and
improved dose conformity may benefit SBRT as an abla-
tive process. Nevertheless, the quantitation of any advan-
tage obtained by smaller leaf width MLC systems over the
5 mm leaf width MLC has remained controversial
[13,14,16,19,20,23].
In the present study, the potential clinical benefit of a
novel 2.5 mm leaf width MLC system over a clinically
available 5 mm leaf width MLC system was explored for
different SBRT treatment planning techniques of lung and
liver lesions. A variety of target dose parameters were con-
sidered, including mean, minimum and maximum PTV
doses; conformity and heterogeneity indices; and normal
tissue sparing. Wu et al. [23], in a similar study on a subset
of five liver cancer patients, showed that the HD120 MLC
system has no significant impact on Dmin, Dmax, or Dmean
values relative to the M120 MLC system. These results
were in agreement with findings in the current study.
Nonetheless, unlike results in Additional file 1 of the cur-
rent study, Wu et al. [23] reported significantly reduced
Dmax values for the liver patient subgroup (p < 0.01) with
use of IMRT and the HD120 MLC system, albeit small
(<2%) compared with the M120 MLC system.
Regarding dose distribution conformity, results in Addi-
tional file 2 demonstrated an improvement in conformity
index with target volume for all assessed planning tech-
niques. The IMRT technique showed the best PTV cover-
age of either MLC system, except for large targets (defined
in the current study as ITV ≥ 64 cm3). As indicated in
Tables 2 and 3, in 51.7% of the IMRT cases, use of the
HD120 MLC improved the conformality of the original
plans by a mean value of 3.9% and up to a maximum
value of 18.5%. In 62.1% and 55.2% of the 3DCRT and
DCA cases, respectively, use of the HD120 MLC also
resulted in improved PTV dose conformality. The mean
and maximum improvements were 2.5% and 9.5% for
the 3DCRT technique, and 2.4% and of 8.1% for the DCA
technique, respectively. Nevertheless, the conformity
index difference between the MLC systems is quite small,
regardless of the treatment planning technique (see Addi-
tional file 2), attributable in part to the number of beams
used for treatment planning.
Normal tissue sparing effect of the MLC systems was
assessed, by considering normal tissue outside the PTV
but in the dose volume space as a virtual structure. Similar
to findings by Wu et al. [23], a reduction in normal tissue
dose was observed with the HD120 MLC system, with at
least 19 of the 29 cases per treatment planning technique
having lower volumes exposed to the 90%, 50% and 25%
dose levels. To be specific, at least 65.5%, 72.4%, and
75.9% cases per planning technique had lower normal tis-
sue volumes exposed to the VHS, VIS, and VLS, respectively
(see Table 2). The mean dose reduction attributable to the
HD120 MLC was between 1 – 4% for the 3DCRT and
DCA techniques, and between 2 – 6% for the IMRT tech-
nique. Thus, in terms of dose reduction, the IMRT plans
were apparently better than either 3DCRT or DCA plans.
However, the quantitative normal tissue volumes exposed
to the 90%, 50% and 25% dose levels were smallest for
the DCA technique, irrespective of MLC system.
Regarding treatment planning efficiency, while the
3DCRT and DCA techniques showed little difference in
treatment monitor units between MLC systems, results in
the current study indicated an increase in monitor units,
albeit statistically insignificant, with the HD120 MLC sys-
tem for the IMRT technique. This was attributable to an
increase in the number of MLC segments needed to
deliver the prescribed dose [12,20].
On a final note, the current work is purely a treatment
planning study on a single treatment planning platform
Table 2: Cases where performance of HD120 MLC surpassed that of M120 MLC. 
Technique CI HI VHS VIS VLS
IMRT 15 (51.7%) 22 (75.9%) 19 (65.5%) 24 (82.8%) 22 (75.9%)
3DCRT 18 (62.1%) 15 (51.7%) 21 (72.4%) 21 (72.4%) 25 (86.2%)
DCA 16 (55.2%) 16 (55.2%) 20 (69.0%) 23 (79.3%) 23 (79.3%)
The values in the table are presented as the number of cases and their corresponding ratio (as a percentage) over the 29 patient cases assessed in 
the current study.
Table 3: Mean (top) and max (bottom) percent improvement or 
worsening of HD120 MLC plans over M120 MLC plans.
Technique Improvement (%) Worsening (%)
CI VHS VIS VLS CI VHS VIS VLS
IMRT 3.9 4.6 5.5 3.5 2.1 3.1 8.5 5.1
3DCRT 2.5 2.5 4.6 1.8 2.2 2.0 5.8 2.6
DCA 2.4 2.2 3.0 3.3 2.7 2.7 4.0 5.1
IMRT 18.5 20.4 26.5 22.7 10.4 17.7 27.6 14.0
3DCRT 9.5 9.8 39.4 3.7 13.2 8.7 25.9 3.7
DCA 8.1 6.4 9.4 9.6 13.2 9.8 12.1 34.3Radiation Oncology 2009, 4:22 http://www.ro-journal.com/content/4/1/22
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with no dosimetric verification. The dosimetric differ-
ences reported here are believed to be solely due to the dif-
ferent leaf widths used in the treatment planning, since
our comparisons were performed on the same treatment
planning system for two treatment platforms with similar
open-field beam characteristics, using the same beam con-
figurations, optimization parameters (for IMRT), and
dose constraints. Nevertheless, it should be pointed out
that leaf-width is not the only parameter that is different
between these MLC systems. Factors such as the leaf trans-
mission and leakage (a function of leaf height, material
constituent, and tongue-and-groove), source-to-MLC dis-
tance, are also different and affect dosimetric parameters.
Therefore, the current planning study is not a simple com-
parison for different MLC leaf-widths, but rather a com-
plex comparison of two dose delivery systems with
different leaf-width MLCs [19].
Conclusion
Data derived from the present comparative assessment
suggest dosimetric merit of the high definition MLC sys-
tem over the millennium MLC system. However, the clin-
ical significance of these results warrants further
investigation in order to determine whether the observed
dosimetric advantages translate into outcome improve-
ments.
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